Galectin Therapeutics Inc Unit Cons of 2 shs + 1 Wt
(NASDAQ : GALTU)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
-0.32%72.110.9%$619.68m
CELGCelgene Corporation
0.06%127.651.1%$445.33m
AMGNAmgen Inc.
-0.31%167.291.1%$418.48m
BIIBBiogen Inc.
-0.93%281.771.2%$356.38m
REGNRegeneron Pharmaceuticals, Inc.
0.85%467.982.7%$321.83m
VRTXVertex Pharmaceuticals Incorporated
-0.28%148.131.9%$264.60m
ALXNAlexion Pharmaceuticals, Inc.
-0.91%133.401.9%$217.97m
ILMNIllumina, Inc.
-0.98%189.323.5%$216.35m
SRPTSarepta Therapeutics, Inc.
-0.46%36.7019.8%$138.44m
INCYIncyte Corporation
-0.45%121.192.6%$130.95m
CLVSClovis Oncology, Inc.
2.99%71.9618.0%$129.20m
KITEKite Pharma, Inc.
3.29%130.1816.1%$121.84m
TSROTESARO, Inc.
4.41%113.8614.7%$121.68m
AAgilent Technologies, Inc.
0.62%61.241.5%$119.01m
BMRNBioMarin Pharmaceutical Inc.
-0.07%80.924.4%$108.58m

Company Profile

Galectin Therapeutics, Inc. operates as a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease and cancer. Its drug candidates are based on the method of targeting galectin proteins, which are key mediators of biologic and pathologic function and its focus is on diseases with serious, life-threatening consequences to patients and those where current treatment options are limited. The company was founded by James C. Czirr and Anatole A. Kltyosov on July 10, 2000 and is headquartered in Norcross, GA.